From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of ...

(Bloomberg) -- Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its ...

The decision – first reported by Stat citing Biogen’s head of corporate development, Adam Keeney – is not an exit from the digital health category, but an acknowledgement that Biogen will ...

Adam Feuerstein, and Damian Garde won in the medical reporting category for their investigation revealing that Biogen used a FDA back channel to win approval for a controversial treatment for ...

are joining Cerevel’s board alongside Bain Capital managing directors Adam Koppel and Chris Gordon. The most advanced assets in the portfolio are a D1 partial agonist expected to start phase III ...

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...